RC drilling underway at Excelsior Springs; Permits pending at Laird Lake WHITE ROCK, BRITISH COLUMBIA / ACCESS Newswire / February 5, 2026 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena" or the "Company") is pleased to provide an exploration update from its Excelsior Springs Project in Nevada and its Laird Lake Project in Ontario. Mammoth Minerals Limited (ASX: M79) (formerly Firetail Resources Limited) has been aggressively exploring Excelsior, per its option agreement to earn an 80% interest i ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / February 5, 2026 / ATHA Energy Corp. ("ATHA" or the "Company") (TSXV:SASK)(OTCQB:SASKF)(FRA:X5U) is pleased to announce that it has closed approximately C$63 million in new financing to advance exploration at scale and development of its Angilak Project, Nunavut: further to its press releases dated January 13 and January 22, 2026, the Company has closed its priva ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 22, 2026 / ATHA Energy Corp. ("ATHA" or the "Company") (TSXV:SASK)(OTCQB:SASKF)(FRA:X5U) is pleased to announce that, further to its press release dated January 13th, 2026, the Company has increased the size of its previously announced private placement (the "Offering") with Queen's Road Capital Investment Ltd. ("QRC") due to strong investor demand. ...

Company Overview - Athena Gold Corporation is engaged in mineral exploration and acquisition of mineral property assets, focusing on developing economic precious and base metal properties across North America [2] - The company holds significant projects including the Laird Lake project in Ontario, covering over 7,000 hectares with recent surface sampling results showing up to 373 g/t Au [2] - Athena Gold also has the Excelsior Springs Project in Nevada, spanning over 2,500 hectares and covering at least three historic mines, currently under an earn-in option with Mammoth Minerals Limited [2] Industry Event - The Vancouver Resource Investment Conference (VRIC) is a key event in the junior mining investment sector in Canada, attracting over 5,000 mining investors annually [1] - The 2026 conference will feature over 120 expert speakers and a marketplace of over 300 investment opportunities in the mining industry, ranging from early-stage exploration to advanced producing mines [1]

Core Viewpoint - ATHA Energy Corp. has announced a binding term sheet with Queen's Road Capital Investment Ltd. for a private placement of USD$20 million in unsecured convertible debentures [1] Group 1: Company Overview - ATHA Energy Corp. is engaging in a private placement to raise capital through the issuance of unsecured convertible debentures [1] - The principal amount of the offering is USD$20 million, which is approximately CAD$27.7 million [1] Group 2: Financial Details - The offering consists of unsecured convertible debentures, indicating a potential for conversion into equity at a later date [1] - The transaction is expected to enhance the company's financial position and support its growth initiatives [1]

Core Viewpoint - Athira Pharma, Inc. has rebranded as LeonaBio, Inc. to reflect its strategic focus on developing lasofoxifene for metastatic breast cancer treatment, currently in Phase 3 trials [1][2] Company Overview - LeonaBio is a clinical-stage biopharmaceutical company focused on innovative therapeutics for diseases with high unmet medical needs, including metastatic breast cancer and amyotrophic lateral sclerosis (ALS) [10] - The company aims to advance a pipeline of late-stage assets to maximize clinical and commercial impact [2] Name and Ticker Change - The name change to LeonaBio symbolizes strength and resilience, aligning with the company's mission to support patients facing serious diseases [2] - The new ticker symbol "LONA" will be effective on January 12, 2026, on The Nasdaq Capital Market [1] Lead Drug Candidates - Lasofoxifene and ATH-1105 are the lead drug candidates, targeting treatment-resistant metastatic breast cancer and ALS, respectively [3][10] - Lasofoxifene is in a Phase 3 trial (ELAINE-3) with over 50% enrollment, and data is expected in mid-2027 [3][6] Licensing and Financing - LeonaBio secured an exclusive global license for lasofoxifene from Sermonix Pharmaceuticals, excluding Asia and certain Middle Eastern countries [4] - The company raised $90 million through a private placement, with potential additional funding of up to $146 million from warrants, to support lasofoxifene's development [4] Drug Candidate Details - Lasofoxifene is a selective estrogen receptor modulator (SERM) designed to target both wild-type and mutant estrogen receptors, addressing a critical unmet need in metastatic breast cancer [5] - ATH-1105 is a next-generation small molecule aimed at treating neurodegenerative diseases, currently in Phase 1 trials with plans for a Phase 2 trial in ALS patients in early 2026 [7][8]

Core Viewpoint - Athira Pharma, Inc. has rebranded as LeonaBio, Inc. following the acquisition of rights to develop and commercialize lasofoxifene for metastatic breast cancer, reflecting the company's commitment to innovation and leadership in addressing unmet medical needs [1][2] Group 1: Company Name Change and Strategy - The name change to LeonaBio symbolizes strength and resilience, aligning with the company's mission to deliver transformative therapies for serious diseases [2] - The new ticker symbol "LONA" will be used on The Nasdaq Capital Market starting January 12, 2026, without affecting the company's legal structure or operations [1][2] Group 2: Drug Development Focus - LeonaBio's lead drug candidates include lasofoxifene and ATH-1105, targeting treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS) [3][9] - Lasofoxifene is currently in a Phase 3 clinical trial (ELAINE-3), with over 50% enrollment and data expected in mid-2027 [3][6] Group 3: Licensing and Financing - The company secured an exclusive global license for lasofoxifene from Sermonix Pharmaceuticals, with an upfront financing of $90 million and potential additional funding of up to $146 million through warrants [4] - This financing is expected to support lasofoxifene's development through key clinical and regulatory milestones, with sufficient capital for operations into 2028 [4] Group 4: Drug Candidate Details - Lasofoxifene is a selective estrogen receptor modulator (SERM) designed to target both wild-type and mutant estrogen receptors, addressing critical unmet needs in metastatic breast cancer [5] - ATH-1105 is a next-generation small molecule drug candidate aimed at treating neurodegenerative diseases, currently in clinical development for ALS [7][8]

Core Viewpoint - ATHA Energy Corp. has announced the grant of 10,150,000 incentive stock options and 1,300,000 restricted share units to eligible participants under its equity incentive plan [1] Summary by Category Stock Options - The company granted a total of 10,150,000 incentive stock options to certain eligible participants, including directors and officers [1] - The vesting schedule for the options is structured as follows: one-third will vest on the date of issuance, one-third on the six-month anniversary, and the remaining one-third on the twelve-month anniversary of the issuance [1] Restricted Share Units - In addition to stock options, the company also granted 1,300,000 restricted share units to eligible participants under the same equity incentive plan [1]

Core Viewpoint - Athena Gold Corporation has successfully closed the third and final tranche of its private placement financing, raising a total of CDN $3,500,028.99 through the issuance of flow-through and non-flow-through units [1] Financing Details - The third tranche raised proceeds of CDN $502,002.98 by issuing 7,142,900 flow-through units at CDN $0.07 each and 33,333 non-flow-through units at CDN $0.06 each [1] - The total amount raised in the first tranche was CDN $2,727,526.03, while the second tranche raised CDN $270,499.98 [1]

Core Viewpoint - Athira Pharma Inc. is making significant strides in its development pipeline by acquiring rights to lasofoxifene, a drug in a Phase 3 trial for metastatic breast cancer, which is expected to enhance its market position and growth potential [1][2]. Group 1: Acquisition Details - Athira has secured an exclusive global license (excluding Asia and certain Middle Eastern countries) from Sermonix Pharmaceuticals for the development and commercialization of lasofoxifene [2]. - As part of the agreement, Athira will issue a pre-funded warrant to purchase approximately 5.5 million shares at an exercise price of $0.001 per share, along with potential payments of up to $100 million based on commercialization or annual net sales milestones [3]. Group 2: Financing and Development Plans - The company announced a $90 million upfront financing through private placement of common stock and warrants, which could provide an additional $146 million if the warrants are exercised, aimed at supporting the development of lasofoxifene through key clinical and regulatory milestones [4]. - The net proceeds from the financing will be utilized for the development of lasofoxifene for treatment-resistant metastatic breast cancer, other clinical assets, and general corporate purposes [5]. Group 3: Market Performance - Following the announcement, Athira Pharma's stock surged by 74.49% to $7.22, reaching a new 52-week high, indicating strong market confidence in the company's future prospects [5].